3/19
09:00 am
ADVM
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
3/19
08:52 am
ADVM
Rating for ADVM
Medium
Report
Rating for ADVM
3/19
08:12 am
ADVM
Rating for ADVM
Medium
Report
Rating for ADVM
3/19
08:12 am
ADVM
Rating for ADVM
Medium
Report
Rating for ADVM
2/6
02:15 pm
ADVM
Rating for ADVM
High
Report
Rating for ADVM
2/6
02:15 pm
ADVM
Rating for ADVM
High
Report
Rating for ADVM